Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-15), Stella Pharma's 14-Day RSI is 57.88.
The industry rank for Stella Pharma's 14-Day RSI or its related term are showing as below:
TSE:4888's 14-Day RSI is ranked worse than 63.09% of 1417
companies
in the Biotechnology industry
Industry Median: 51.69
vs TSE:4888: 57.88
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Stella Pharma 14-Day RSI Related Terms
TSE:4888 vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Stella Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Stella Pharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stella Pharma (TSE:4888) has a 14-Day RSI of 57.88 as of Aug. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Stella Pharma and its competitors. According to the industry distribution chart, Stella Pharma ranks #894 out of 1417 companies in the Biotechnology industry, placing it in the top 63.1%.
Is Stella Pharma's 14-Day RSI too high?
Stella Pharma's current 14-Day RSI is 57.88. The Biotechnology industry median 14-Day RSI is 51.69. Stella Pharma's value of 57.88 is 12% above this industry median. Based on the distribution chart, Stella Pharma ranks #894 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stella Pharma has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #894 out of 1417 companies for 14-Day RSI. This places Stella Pharma in the lower half of its industry. The industry median 14-Day RSI is 51.69. Stella Pharma's value of 57.88 is 12% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.69, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stella Pharma's current 14-Day RSI of 57.88 is 12% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Stella Pharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stella Pharma's current 14-Day RSI is 57.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Modestly Undervalued. The stock's GF Value™ is 円369.65, compared to a current price of 円333.00 — trading 9.9% below its estimated fair value. The current 14-Day RSI is 57.88 and 12% above the Biotechnology industry median of 51.69. Stella Pharma's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current 14-Day RSI is 57.88 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円333.00 is trading 9.9% below its estimated GF Value™ of 円369.65.
GuruFocus considers Stella Pharma to be Modestly Undervalued.
Key valuation signals for TSE:4888:
14-Day RSI: 57.88
GF Value™: 円369.65 vs. price of 円333.00 (9.9% below fair value)
Industry Position: 12% above the Biotechnology median (#894 of 1417)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
76GF Score
Get the complete analysis for TSE:4888
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
